8-K: Candel Therapeutics Reports Q3 2024 Financial Results and Provides Clinical Program Update

Candel Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical programs, including expected topline data readouts for CAN-2409 in prostate cancer in Q4 2024.

Summary

• Candel Therapeutics reported a net loss of $10.6 million for the third quarter of 2024, compared to a net loss of $8.4 million for the same period in 2023.
• Research and development expenses decreased to $5.4 million from $5.8 million year-over-year, primarily due to lower payroll costs following a corporate restructuring.
• General and administrative expenses increased to $3.3 million from $3.0 million year-over-year, mainly due to higher professional and consulting fees.
• The company's cash and cash equivalents were $16.6 million as of September 30, 2024, down from $35.4 million at the end of 2023.
• Candel expects its current cash to fund operations through the end of Q1 2025.
• The company is on track to report topline data for CAN-2409 in prostate cancer in Q4 2024.
• Preclinical data for CAN-3110 in melanoma was presented at the SITC 2024 Annual Meeting, showing promising results.
• Updated overall survival data from CAN-2409 trials in NSCLC and pancreatic cancer are expected in Q1 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical updates and progress in research, the financial situation is concerning with increased losses and a rapidly decreasing cash balance. The need for a capital raise is a significant risk.

Positives

• The company is on track to deliver key data readouts for CAN-2409 in Q4 2024.
• CAN-3110 has shown promising clinical and preclinical results, including improved survival in rHGG patients and anti-tumor activity in melanoma models.
• The enLIGHTEN Discovery Platform is generating new therapeutic candidates.
• CAN-3110 received orphan drug designation from the FDA for rHGG.
• The company has sufficient cash to fund operations through Q1 2025.

Negatives

• The company experienced a net loss of $10.6 million in Q3 2024, an increase from $8.4 million in Q3 2023.
• Cash reserves have decreased significantly from $35.4 million at the end of 2023 to $16.6 million as of September 30, 2024.
• The company's working capital has decreased significantly from $22.6 million to $2.8 million.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• Clinical trial results may differ from reported interim data.
• The company faces risks related to the timing and advancement of development programs.
• The company's ability to obtain and maintain regulatory approval of product candidates is not guaranteed.
• The company's ability to maintain its intellectual property is not guaranteed.

Future Outlook

The company anticipates topline data readouts for CAN-2409 in prostate cancer in Q4 2024 and updated overall survival data from CAN-2409 trials in NSCLC and pancreatic cancer in Q1 2025. The company expects its current cash to fund operations through the end of Q1 2025.

Management Comments

• We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter of 2024, and hope we will deliver the data and regulatory approvals to enable a paradigm shift in how these patients will be treated in the future.
• We continue to advance our clinical and pre-clinical candidates, while leveraging our robust enLIGHTENTM Discovery Platform to identify new and innovative assets that may be impactful in cancer immunotherapy.
• We are encouraged by the first clinical and biomarker activity data after repeated injection of CAN-3110 from our ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma, which suggests a long tail of survival.
• As to the future, we are also looking forward to reporting updated overall survival data from both our ongoing CAN-2409 phase 2 NSCLC and pancreatic cancer clinical trials in Q1 2025.

Industry Context

Candel's focus on multimodal biological immunotherapies aligns with the broader industry trend towards personalized cancer treatments. The company's clinical programs in prostate cancer, melanoma, and high-grade glioma address significant unmet medical needs. The use of viral vectors for gene therapy is also a growing area of interest in the biotech industry.

Comparison to Industry Standards

• Candel's cash burn rate is high, with a net loss of $10.6 million in Q3 2024, which is not uncommon for clinical-stage biotech companies.
• The company's cash runway to the end of Q1 2025 is relatively short, requiring them to raise additional capital soon, similar to other companies in the sector.
• The clinical trial timelines for CAN-2409 are consistent with industry standards for phase 2b and phase 3 trials.
• The preclinical data for CAN-3110 in melanoma is promising, but further clinical trials are needed to validate these findings, similar to other companies developing novel cancer therapies.
• Companies like BioNTech and Moderna have also seen success with novel cancer therapies, but they have much larger market caps and more advanced pipelines.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves.
• Employees may be concerned about the company's financial stability and potential for future restructuring.
• Patients may be hopeful about the potential of Candel's therapies to treat cancer.
• Creditors may be concerned about the company's ability to repay debts.

Next Steps

• The company will release topline data for CAN-2409 in prostate cancer in Q4 2024.
• The company will report updated overall survival data from CAN-2409 trials in NSCLC and pancreatic cancer in Q1 2025.
• The company will continue to advance its clinical and preclinical programs.
• The company will likely need to raise additional capital to fund operations beyond Q1 2025.

Key Dates

Keywords

Candel Therapeutics, CAN-2409, CAN-3110, Prostate Cancer, Melanoma, High-Grade Glioma, Immunotherapy, Clinical Trials, Orphan Drug Designation, enLIGHTEN Discovery Platform